Literature DB >> 24488617

The difference in miR-21 expression levels between invasive and non-invasive breast cancers emphasizes its role in breast cancer invasion.

Nina Petrović1, Vesna Mandušić, Boban Stanojević, Silvana Lukić, Lidija Todorović, Jelena Roganović, Bogomir Dimitrijević.   

Abstract

MicroRNA-21 (miR-21) overexpression is characteristic for various types of tumors, but it is still unknown whether its expression levels differ between invasive and non-invasive breast carcinomas. The main goal of the study was to determine the difference in miR-21 expression among normal tissue, non-invasive, invasive with non-invasive component, and pure invasive breast cancer samples, to explain its potential role and significance in breast cancer invasiveness. The second goal was to propose miR-21 as molecular marker of breast cancer invasiveness and potential target for future anti-miR therapies for the prevention of invasion and metastasis. In order to reveal the role of miR-21 in breast cancer invasiveness, we measured miR-21 expression levels in 44 breast cancer and four normal samples by stem-loop real-time RT-PCR using TaqMan technology. Relative expression levels of miR-21 were significantly higher in invasive than in other groups (P=0.002) and significantly higher in invasive compared with invasive with non-invasive component group in histological (P=0.043) and nuclear grade 2 (P=0.036), estrogen-receptor-positive (ER+) (P=0.006), progesterone-receptor-positive (PR+) (P=0.008), ER+PR+ (P=0.007), and proliferation index (Ki-67)≤20% (P=0.036) tumors. Our findings suggest that miR-21 could be independent molecular marker of breast cancer invasiveness and potential target for future anti-miR therapies for the prevention of invasion and metastasis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24488617     DOI: 10.1007/s12032-014-0867-x

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  30 in total

1.  Preparation and characterization of recombinant tissue inhibitor of metalloproteinase 4 (TIMP-4).

Authors:  Y E Liu; M Wang; J Greene; J Su; S Ullrich; H Li; S Sheng; P Alexander; Q A Sang; Y E Shi
Journal:  J Biol Chem       Date:  1997-08-15       Impact factor: 5.157

2.  Novel human PDCD4 (H731) gene expressed in proliferative cells is expressed in the small duct epithelial cells of the breast as revealed by an anti-H731 antibody.

Authors:  H Yoshinaga; S Matsuhashi; C Fujiyama; Z Masaki
Journal:  Pathol Int       Date:  1999-12       Impact factor: 2.534

3.  Membrane type 1 matrix metalloprotease cleaves laminin-10 and promotes prostate cancer cell migration.

Authors:  Elisabeth L Bair; Man Ling Chen; Kathy McDaniel; Kiyotoshi Sekiguchi; Anne E Cress; Raymond B Nagle; George Timothy Bowden
Journal:  Neoplasia       Date:  2005-04       Impact factor: 5.715

4.  MicroRNA-21 regulates breast cancer invasion partly by targeting tissue inhibitor of metalloproteinase 3 expression.

Authors:  Bao Song; Chuanxi Wang; Jie Liu; Xingwu Wang; Liyan Lv; Ling Wei; Li Xie; Yan Zheng; Xianrang Song
Journal:  J Exp Clin Cancer Res       Date:  2010-03-27

5.  Immunohistochemical detection of steroid receptors in breast cancer: a working protocol. UK Receptor Group, UK NEQAS, The Scottish Breast Cancer Pathology Group, and The Receptor and Biomarker Study Group of the EORTC.

Authors:  R Leake; D Barnes; S Pinder; I Ellis; L Anderson; T Anderson; R Adamson; T Rhodes; K Miller; R Walker
Journal:  J Clin Pathol       Date:  2000-08       Impact factor: 3.411

6.  Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells.

Authors:  Lisa B Frankel; Nanna R Christoffersen; Anders Jacobsen; Morten Lindow; Anders Krogh; Anders H Lund
Journal:  J Biol Chem       Date:  2007-11-08       Impact factor: 5.157

7.  Tissue inhibitors of metalloproteinase expression in human breast cancer: TIMP-3 is associated with adjuvant endocrine therapy success.

Authors:  Paul N Span; Raija L P Lindberg; Peggy Manders; Vivianne C G Tjan-Heijnen; Joop J T M Heuvel; Louk V A M Beex; C G J Sweep
Journal:  J Pathol       Date:  2004-04       Impact factor: 7.996

8.  MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1).

Authors:  Shuomin Zhu; Min-Liang Si; Hailong Wu; Yin-Yuan Mo
Journal:  J Biol Chem       Date:  2007-03-15       Impact factor: 5.157

Review 9.  microRNA, cell cycle, and human breast cancer.

Authors:  Zuoren Yu; Renato Baserga; Lide Chen; Chenguang Wang; Michael P Lisanti; Richard G Pestell
Journal:  Am J Pathol       Date:  2010-01-14       Impact factor: 4.307

10.  Prognostic Implications of MicroRNA-21 Overexpression in Invasive Ductal Carcinomas of the Breast.

Authors:  Jung Ah Lee; Hye Yoon Lee; Eun Sook Lee; Insun Kim; Jeoung Won Bae
Journal:  J Breast Cancer       Date:  2011-12-27       Impact factor: 3.588

View more
  16 in total

1.  Dehydroepiandrosterone-induces miR-21 transcription in HepG2 cells through estrogen receptor β and androgen receptor.

Authors:  Yun Teng; Lacey M Litchfield; Margarita M Ivanova; Russell A Prough; Barbara J Clark; Carolyn M Klinge
Journal:  Mol Cell Endocrinol       Date:  2014-05-17       Impact factor: 4.102

Review 2.  Levels of MicroRNA Heterogeneity in Cancer Biology.

Authors:  Nina Petrovic; Sercan Ergün; Esma R Isenovic
Journal:  Mol Diagn Ther       Date:  2017-10       Impact factor: 4.074

3.  Changes in miR-221/222 Levels in Invasive and In Situ Carcinomas of the Breast: Differences in Association with Estrogen Receptor and TIMP3 Expression Levels.

Authors:  Nina Petrovic; Radoslav Davidovic; Snezana Jovanovic-Cupic; Milena Krajnovic; Silvana Lukic; Milan Petrovic; Jelena Roganovic
Journal:  Mol Diagn Ther       Date:  2016-12       Impact factor: 4.074

Review 4.  miRNA - Therapeutic tool in breast cancer? Where are we now?

Authors:  Karolina Zaleska
Journal:  Rep Pract Oncol Radiother       Date:  2014-11-26

5.  Higher miR-21 expression in invasive breast carcinomas is associated with positive estrogen and progesterone receptor status in patients from Serbia.

Authors:  Nina Petrović; Vesna Mandušić; Bogomir Dimitrijević; Jelena Roganović; Silvana Lukić; Lidija Todorović; Boban Stanojević
Journal:  Med Oncol       Date:  2014-04-30       Impact factor: 3.064

Review 6.  miR-21 Might be Involved in Breast Cancer Promotion and Invasion Rather than in Initial Events of Breast Cancer Development.

Authors:  Nina Petrović
Journal:  Mol Diagn Ther       Date:  2016-04       Impact factor: 4.074

7.  Stat3 regulates ErbB-2 expression and co-opts ErbB-2 nuclear function to induce miR-21 expression, PDCD4 downregulation and breast cancer metastasis.

Authors:  L Venturutti; L V Romero; A J Urtreger; M F Chervo; R I Cordo Russo; M F Mercogliano; G Inurrigarro; M G Pereyra; C J Proietti; F Izzo; M C Díaz Flaqué; V Sundblad; J C Roa; P Guzmán; E D Bal de Kier Joffé; E H Charreau; R Schillaci; P V Elizalde
Journal:  Oncogene       Date:  2015-07-27       Impact factor: 9.867

8.  Feasibility of urinary microRNA detection in breast cancer patients and its potential as an innovative non-invasive biomarker.

Authors:  Thalia Erbes; Marc Hirschfeld; Gerta Rücker; Markus Jaeger; Jasmin Boas; Severine Iborra; Sebastian Mayer; Gerald Gitsch; Elmar Stickeler
Journal:  BMC Cancer       Date:  2015-03-28       Impact factor: 4.430

Review 9.  Breast Cancer Response to Therapy: Can microRNAs Lead the Way?

Authors:  Nina Petrović; Irina Nakashidze; Milica Nedeljković
Journal:  J Mammary Gland Biol Neoplasia       Date:  2021-01-21       Impact factor: 2.673

10.  MicroRNA‑21 regulates the expression of BTG2 in HepG2 liver cancer cells.

Authors:  Bijing Mao; He Xiao; Zhimin Zhang; Dong Wang; Ge Wang
Journal:  Mol Med Rep       Date:  2015-07-07       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.